Among the 73 breast angiosarcoma samples (representing 72 patients), we found recurrent MYC amplification (35/73, 47.9%), as well as alterations in KDR/VEGFR2 (17/73, 23.3%), FLT4/VEGFR3 (11/73, 15.1%), PIK3CA (9/73, 12.3%), KMT2D (10/73, 13.7%), and TP53 (4/73, 5.5%) (Table 3). This evidence concerns the gene FLT4 and medical procedure.